Cargando…
The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures
Background: Approximately 71 million people are still in need of direct-acting antiviral agents (DAAs). To achieve the World Health Organization Hepatitis C elimination goals, insight into the prevalence and influence of resistance associated substitutions (RAS) is of importance. Collaboration is ke...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781716/ https://www.ncbi.nlm.nih.gov/pubmed/35062220 http://dx.doi.org/10.3390/v14010016 |
_version_ | 1784638145473544192 |
---|---|
author | Popping, Stephanie Cento, Valeria Seguin-Devaux, Carole Boucher, Charles A. B. de Salazar, Adolfo Heger, Eva Mor, Orna Sayan, Murat Salmon-Ceron, Dominique Weis, Nina Krarup, Henrik B. de Knegt, Robert J. Săndulescu, Oana Chulanov, Vladimir van de Vijver, David A. M. C. García, Federico Ceccherini-Silberstein, Francesca |
author_facet | Popping, Stephanie Cento, Valeria Seguin-Devaux, Carole Boucher, Charles A. B. de Salazar, Adolfo Heger, Eva Mor, Orna Sayan, Murat Salmon-Ceron, Dominique Weis, Nina Krarup, Henrik B. de Knegt, Robert J. Săndulescu, Oana Chulanov, Vladimir van de Vijver, David A. M. C. García, Federico Ceccherini-Silberstein, Francesca |
author_sort | Popping, Stephanie |
collection | PubMed |
description | Background: Approximately 71 million people are still in need of direct-acting antiviral agents (DAAs). To achieve the World Health Organization Hepatitis C elimination goals, insight into the prevalence and influence of resistance associated substitutions (RAS) is of importance. Collaboration is key since DAA failure is rare and real-life data are scattered. We have established a European collaboration, HepCare, to perform in-depth analysis regarding RAS prevalence, patterns, and multiclass occurrence. Methods: Data were extracted from the HepCare cohort of patients who previously failed DAA therapy. Geno—and subtypes were provided by submitters and mostly based on in-house assays. They were reassessed using the Comet HCV subtyping tool. We considered RAS to be relevant if they were associated with DAA failure in vivo previously reported in literature. Results: We analyzed 938 patients who failed DAA therapy from ten different European countries. There were 239 genotypes (GT) 1a, 380 GT1b, 19 GT2c, 205 GT3a, 14 GT4a, and 68 GT4d infections. Several unusual subtypes (n = 15) (GT1b/g/l, GT3b, GT4k/n/r/t) were present. RAS appeared in over 80% of failures and over a quarter had three or more RAS. Multiclass RAS varied over target region and genotype between 0–48%. RAS patterns such as the Q30R + L31M and Q30R + Y93H in GT1a, the L31V + Y93H and L31V + Y93H for GT1b, and A30K + L31M and A30K/V + Y93H for GT3a all occurred with a prevalence below 5%. Conclusion: RAS occur frequently after DAA failures and follow a specific genotype and drug related pattern. Interpretation of the influence of RAS on retreatment is challenging due to various patterns, patients’ characteristics, and previous treatment history. Moving towards HCV elimination, an ongoing resistance surveillance is essential to track the presence of RAS, RAS patterns and gather data for a re-treatment algorithm. |
format | Online Article Text |
id | pubmed-8781716 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87817162022-01-22 The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures Popping, Stephanie Cento, Valeria Seguin-Devaux, Carole Boucher, Charles A. B. de Salazar, Adolfo Heger, Eva Mor, Orna Sayan, Murat Salmon-Ceron, Dominique Weis, Nina Krarup, Henrik B. de Knegt, Robert J. Săndulescu, Oana Chulanov, Vladimir van de Vijver, David A. M. C. García, Federico Ceccherini-Silberstein, Francesca Viruses Article Background: Approximately 71 million people are still in need of direct-acting antiviral agents (DAAs). To achieve the World Health Organization Hepatitis C elimination goals, insight into the prevalence and influence of resistance associated substitutions (RAS) is of importance. Collaboration is key since DAA failure is rare and real-life data are scattered. We have established a European collaboration, HepCare, to perform in-depth analysis regarding RAS prevalence, patterns, and multiclass occurrence. Methods: Data were extracted from the HepCare cohort of patients who previously failed DAA therapy. Geno—and subtypes were provided by submitters and mostly based on in-house assays. They were reassessed using the Comet HCV subtyping tool. We considered RAS to be relevant if they were associated with DAA failure in vivo previously reported in literature. Results: We analyzed 938 patients who failed DAA therapy from ten different European countries. There were 239 genotypes (GT) 1a, 380 GT1b, 19 GT2c, 205 GT3a, 14 GT4a, and 68 GT4d infections. Several unusual subtypes (n = 15) (GT1b/g/l, GT3b, GT4k/n/r/t) were present. RAS appeared in over 80% of failures and over a quarter had three or more RAS. Multiclass RAS varied over target region and genotype between 0–48%. RAS patterns such as the Q30R + L31M and Q30R + Y93H in GT1a, the L31V + Y93H and L31V + Y93H for GT1b, and A30K + L31M and A30K/V + Y93H for GT3a all occurred with a prevalence below 5%. Conclusion: RAS occur frequently after DAA failures and follow a specific genotype and drug related pattern. Interpretation of the influence of RAS on retreatment is challenging due to various patterns, patients’ characteristics, and previous treatment history. Moving towards HCV elimination, an ongoing resistance surveillance is essential to track the presence of RAS, RAS patterns and gather data for a re-treatment algorithm. MDPI 2021-12-22 /pmc/articles/PMC8781716/ /pubmed/35062220 http://dx.doi.org/10.3390/v14010016 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Popping, Stephanie Cento, Valeria Seguin-Devaux, Carole Boucher, Charles A. B. de Salazar, Adolfo Heger, Eva Mor, Orna Sayan, Murat Salmon-Ceron, Dominique Weis, Nina Krarup, Henrik B. de Knegt, Robert J. Săndulescu, Oana Chulanov, Vladimir van de Vijver, David A. M. C. García, Federico Ceccherini-Silberstein, Francesca The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures |
title | The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures |
title_full | The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures |
title_fullStr | The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures |
title_full_unstemmed | The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures |
title_short | The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures |
title_sort | european prevalence of resistance associated substitutions among direct acting antiviral failures |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781716/ https://www.ncbi.nlm.nih.gov/pubmed/35062220 http://dx.doi.org/10.3390/v14010016 |
work_keys_str_mv | AT poppingstephanie theeuropeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT centovaleria theeuropeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT seguindevauxcarole theeuropeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT bouchercharlesab theeuropeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT desalazaradolfo theeuropeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT hegereva theeuropeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT mororna theeuropeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT sayanmurat theeuropeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT salmoncerondominique theeuropeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT weisnina theeuropeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT kraruphenrikb theeuropeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT deknegtrobertj theeuropeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT sandulescuoana theeuropeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT chulanovvladimir theeuropeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT vandevijverdavidamc theeuropeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT garciafederico theeuropeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT ceccherinisilbersteinfrancesca theeuropeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT poppingstephanie europeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT centovaleria europeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT seguindevauxcarole europeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT bouchercharlesab europeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT desalazaradolfo europeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT hegereva europeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT mororna europeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT sayanmurat europeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT salmoncerondominique europeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT weisnina europeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT kraruphenrikb europeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT deknegtrobertj europeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT sandulescuoana europeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT chulanovvladimir europeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT vandevijverdavidamc europeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT garciafederico europeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures AT ceccherinisilbersteinfrancesca europeanprevalenceofresistanceassociatedsubstitutionsamongdirectactingantiviralfailures |